Novo Nordisk Q2 2026 Earnings Tuesday August 4 Report Sales of 78.49 Billion Danish Kroner ($12.09 Billion, +3% Constant Currency, +7% Adjusted Sales); Wegovy Injectable Reached 19.484 Billion DKK (+1% YoY), Wegovy Pill (Oral Semaglutide 25/50 mg for Obesity, Launched Q1 2026) Generated 3.218 Billion DKK on More Than 5 Million Cumulative Prescriptions Since Launch, and Ozempic (Semaglutide for Type 2 Diabetes) Grew 3% to 31.375 Billion DKK; 2026 Adjusted Sales Guidance Hiked From Prior Range to Down 6% to Flat at Constant Exchange Rates on the Wegovy Pill Strength
Novo Nordisk reported Q2 2026 earnings Tuesday August 4, 2026 with sales of 78.49 billion Danish kroner ($12.09 billion, +3% constant currency, +7% adjusted). Franchise performance: Wegovy injectable reached 19.484 billion DKK (+1% year-over-year); Wegovy pill (oral semaglutide 25/50 mg for obesity, launched Q1 2026) generated 3.218 billion DKK on more than 5 million cumulative prescriptions since launch; Ozempic (semaglutide for type 2 diabetes) grew 3% to 31.375 billion DKK. Novo Nordisk hiked its 2026 adjusted sales guidance to down 6% to flat at constant exchange rates, an improvement from the previous guidance that had reflected the substantially compressed pricing environment from the Trump administration Most-Favored-Nation deals and the July 1 Medicare GLP-1 Bridge Program launch. The Wegovy pill launch trajectory (5 million prescriptions in roughly six months) is one of the fastest oral obesity-drug uptake curves on record and effectively confirms the strength of the SNAC-enhanced oral peptide formulation strategy that Novo has pursued since the 2019 Rybelsus approval for type 2 diabetes. Novo shares tanked despite the raised outlook, reflecting concern about the tough Q2 2025 comparison and margin trajectory into 2027.